Concepedia

Marion de Jong

MD

Statistics

Publications

164

Citations

12K

H-Index

60

Active since

1972

Affiliations

Erasmus MC(Current)

Erasmus University Rotterdam

National Centre of Scientific Research "Demokritos"

Radboud University Nijmegen

Radboud University Medical Center

Marion de Jong is an author at Erasmus MC specializing in medicine, radionuclide therapy, and nuclear medicine.

ORCID

Publications per year

1972–2022

164

Publications

164

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 471 citations

, , +3

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 433 citations

, , +14

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

E. P. Krenning, WH Bakker, P P Kooij et al. · PubMed · 1992 · 422 citations

, , +16

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 422 citations · Full text

, , +10

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Roelf Valkema, Stanislas Pauwels, Larry K. Kvols et al. · PubMed · 2005 · 334 citations · Full text

, , +16

1–5 of 164